ALPHA1 THERAPY REFERRAL FORM

Phone (888) 370.1724 Fax (855) 370.0086



Patient Information	PLEASE FAX IN	SURANCE CA	ARD (FRONT AI	ND BACK)	Prescriber Info	ormatio	on	
Last Name First Name		1	DOB		Practice/Facility Name			
Address	•				Address			
City State			ZIP		City		State ZIP	
Phone SSN			•		Prescriber Name			
Allergies Latex Allergy Yes No				No	Prescriber NPI			
Sex Male Female	Weight (kg)		Height (ft,in)		Nurse/Key Contact		Phone/Page	ər
Insurance Plan ID #		Plan ID #			Fax		Email	
Diagnosis and Clini	cal Informatio	n					•	
Diagnosis (ICD-10): E88.01 (Congenital Emphy Patient Clinical Information:					Descriptio			Other:
Allergies:					omp to			
FEV1:% predicted	opt) md/dl	or	microM Nursii	ng: Please ar	range nursing adminis	tration	Patient may be	taught to self-infuse
Serum A1AT levels (pretreatm Does the patient display clinic			No					
		100	110					
Prescription Inform	ation							
Medication			Dose and Di	rections			Quantity	Refills
Aralast®	60mg/kg via IV	infusion once	every week	other				
	mg/kg via IV infusion once every week other					-	4 week sup	ply 1 year
Glassia®		5/118/114/11	usion once ever	ry week oth	ner	-	4 week sup 12 week su	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
	60mg/kg via IV					- - -		pply
		infusion once		other	ner	- - -	12 week su	pply ply 1 year
Zemaira®	60mg/kg via IV	infusion once g/kg via IV infi infusion once	every week usion once ever every week	other ry week oth other	ner	_	12 week sup 4 week sup 12 week sup 4 week sup	pply ply 1 year pply ply 1 year
	mg 60mg/kg via IV mg	infusion once g/kg via IV infi infusion once g/kg via IV infi	every week usion once ever every week usion once ever	other ry week oth other ry week oth	ner	_	12 week sup 4 week sup 12 week sup 4 week sup 12 week su	pply ply 1 year pply ply 1 year
Epinephrine® IM	mi 60mg/kg via IV mg Adult 1:1000, 0.	infusion once g/kg via IV infu infusion once g/kg via IV infu 3mL (>30kg/	every week usion once ever every week usion once ever >66lbs)	other ry week oth other y week oth PRN Anap	ner	_	12 week sup 4 week sup 12 week sup 4 week sup	pply ply 1 year pply ply 1 year
Epinephrine®	mg 60mg/kg via IV mg Adult 1:1000, 0. Peds 1:2000, 0.	infusion once g/kg via IV infu infusion once g/kg via IV infu 3mL (>30kg/	every week usion once ever every week usion once ever >66lbs)	other ry week oth other y week oth PRN Anap	ner	_	12 week sup 4 week sup 12 week sup 4 week sup 12 week su Once	pply ply 1 year pply ply 1 year pply
Epinephrine® IM SQ Normal Saline	mg 60mg/kg via IV mg Adult 1:1000, 0. Peds 1:2000, 0. 3mL	infusion once g/kg via IV infu infusion once g/kg via IV infu 3mL (>30kg/	every week usion once ever every week usion once ever >66lbs)	other y week oth other y week oth PRN Anap Repeating	ner	_	12 week sup 4 week sup 12 week sup 12 week sup 12 week sup 12 week sup 0nce 1 month	pply ply 1 year pply ply 1 year pply
Epinephrine® IM SQ	mg 60mg/kg via IV mg Adult 1:1000, 0. Peds 1:2000, 0.	infusion once g/kg via IV infu infusion once g/kg via IV infu 3mL (>30kg/ 3mL (15-30kg	every week usion once ever every week usion once ever '>66lbs) g/33-66lbs)	other y week oth other y week oth PRN Anap Repeating	ner ner ner hylaxis § Dose:	_	12 week sup 4 week sup 12 week sup 4 week sup 12 week su Once	pply ply 1 year pply ply 1 year ply 1 year 1 year
Epinephrine® IM SQ Normal Saline D5W	mg 60mg/kg via IV mg Adult 1:1000, 0. Peds 1:2000, 0. 3mL 5mL	infusion once g/kg via IV infu infusion once g/kg via IV infu 3mL (>30kg/ 3mL (15-30kg	every week usion once ever every week usion once ever '>66lbs) g/33-66lbs)	other y week oth other y week oth PRN Anap Repeating IV before a	ner ner ner hylaxis g Dose: and after infusion	_	12 week sup 4 week sup 12 week sup 12 week sup 12 week sup 12 week sup 0nce 1 month	pply ply 1 year pply ply 1 year pply 1 year 1 year
Epinephrine® IM SQ Normal Saline	mg 60mg/kg via IV mg Adult 1:1000, 0. Peds 1:2000, 0. 3mL 5mL Other	infusion once g/kg via IV infu infusion once g/kg via IV infu 3mL (>30kg/ 3mL (15-30kg	every week usion once ever every week usion once ever '>66lbs) g/33-66lbs)	other y week oth other y week oth PRN Anap Repeating IV before a	ner ner ner hylaxis § Dose:	_	12 week sup 4 week sup 12 week sup 12 week sup 12 week sup 12 week su Once 1 month 3 months	pply ply 1 year pply ply 1 year ply 1 year 1 year
Epinephrine® IM SQ Normal Saline D5W Heparin 10 units/mL	mg 60mg/kg via IV mg Adult 1:1000, 0. Peds 1:2000, 0. 3mL 5mL Other 3mL	infusion once g/kg via IV infu infusion once g/kg via IV infu 3mL (>30kg/ 3mL (15-30kg	every week usion once ever every week usion once ever 7>66lbs) g/33-66lbs)	other y week oth other y week oth PRN Anap Repeating IV before a	ner ner ner hylaxis g Dose: and after infusion	_	12 week sup 12 week sup 12 week sup 12 week sup 12 week su Once 1 month 3 months 1 month	pply ply 1 year pply ply 1 year pply 1 year 1 year
Epinephrine® IM SQ Normal Saline D5W Heparin 10 units/mL	mg 60mg/kg via IV mg Adult 1:1000, 0. Peds 1:2000, 0. 3mL 5mL Other 3mL 5mL	infusion once g/kg via IV infu infusion once g/kg via IV infu 3mL (>30kg/ 3mL (15-30kg	every week usion once ever every week usion once ever 7>66lbs) g/33-66lbs)	other y week oth other y week oth PRN Anap Repeating IV before a	ner ner ner hylaxis g Dose: and after infusion	_	12 week sup 12 week sup 12 week sup 12 week sup 12 week su Once 1 month 3 months 1 month	pply ply 1 year pply ply 1 year pply 1 year 1 year

In order for a brand name product to be dispensed, the prescriber must handwrite "Brand Necessary" or "Brand Medically Necessary," or your state-specific required language to prohibit substitution:

PRESCRIBER MUST MANUALLY SIGN - STAMP SIGNATURE, SIGNATURE BY OTHER PERSONNEL AND COMPUTER-GENERATED SIGNATURES WILL NOT BE ACCEPTED

PRODUCT SUBSTITUTION PERMITTED/Brand exchange permitted (date)

Method:

DISPENSE AS WRITTEN/Do Not Substitute

(date)

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.